ridm@nrct.go.th   ระบบคลังข้อมูลงานวิจัยไทย   รายการโปรดที่คุณเลือกไว้

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer

หน่วยงาน มหาวิทยาลัยเชียงใหม่

รายละเอียด

ชื่อเรื่อง : Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer
นักวิจัย : Mok T.S. , Geater S.L. , Iannotti N. , Thongprasert S. , Spira A. , Smith D. , Lee V. , Lim W.T. , Reyderman L. , Wang B. , Gopalakrishna P. , Garzon F. , Xu L. , Reynolds C.
คำค้น : -
หน่วยงาน : มหาวิทยาลัยเชียงใหม่
ผู้ร่วมงาน : -
ปีพิมพ์ : 2557
อ้างอิง : 15698041 , 10.1093/annonc/mdu174 , ANONE , http://www.scopus.com/inward/record.url?eid=2-s2.0-84905162106&partnerID=40&md5=c014ad669a6469cce38f40b39d5fcc99 , http://cmuir.cmu.ac.th/handle/6653943832/1781
ที่มา : -
ความเชี่ยวชาญ : -
ความสัมพันธ์ : -
ขอบเขตของเนื้อหา : -
บทคัดย่อ/คำอธิบาย :

Background: This phase II, open-label study investigated intercalated combinations of eribulin and erlotinib in unselected patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapies. Patients and methods: Eligible patients were randomized to eribulin mesylate 2.0 mg/m2 on day 1 with erlotinib 150 mg on days 2-16 (21-day regimen) or eribulin mesylate 1.4 mg/m2 on days 1 and 8 with erlotinib 150 mg on days 15-28 (28-day regimen). The primary end point was objective response rate (ORR). Results: One hundred and twenty-three patients received ≥1 cycle of therapy (63, 21-day regimen; 60, 28-day regimen). ORRs were 13% [95% confidence interval (CI) 6%-24%] and 17% (95% CI 8%-29%), and disease control rates were 48% (95% CI 35%-61%) and 63% (95% CI 50%-75%) for the 21- and 28-day regimens, respectively. The median progression-free survival and overall survival were similar with both regimens. Both regimens were well tolerated with common grade ≥3 toxicities being neutropenia, asthenia/fatigue, and dyspnoea. Sequential administration of erlotinib did not interfere with the pharmacokinetic profile of eribulin. Conclusion: Intercalated combination of eribulin and erlotinib demonstrated modest activity and the addition of erlotinib did not appear to improve treatment outcome in an unselected population. The 28-day regimen is suitable for further investigation. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

บรรณานุกรม :
Mok T.S. , Geater S.L. , Iannotti N. , Thongprasert S. , Spira A. , Smith D. , Lee V. , Lim W.T. , Reyderman L. , Wang B. , Gopalakrishna P. , Garzon F. , Xu L. , Reynolds C. . (2557). Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer.
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Mok T.S. , Geater S.L. , Iannotti N. , Thongprasert S. , Spira A. , Smith D. , Lee V. , Lim W.T. , Reyderman L. , Wang B. , Gopalakrishna P. , Garzon F. , Xu L. , Reynolds C. . 2557. "Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer".
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Mok T.S. , Geater S.L. , Iannotti N. , Thongprasert S. , Spira A. , Smith D. , Lee V. , Lim W.T. , Reyderman L. , Wang B. , Gopalakrishna P. , Garzon F. , Xu L. , Reynolds C. . "Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer."
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2557. Print.
Mok T.S. , Geater S.L. , Iannotti N. , Thongprasert S. , Spira A. , Smith D. , Lee V. , Lim W.T. , Reyderman L. , Wang B. , Gopalakrishna P. , Garzon F. , Xu L. , Reynolds C. . Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2557.